Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckPRO: SBRT + Ipilimumab/Nivolumab in mCRPC
NCT05655715Phase 2Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Nov 2019
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Herlev & Gentofte Hospital. Started Nov 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05655715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05655715.